ANVS Archives - BioTuesdays

Developments

Annovis Bio to expand Phase 3 PD study of buntanetap to EU

Annovis Bio (NYSE:ANVS) received approval to open 48 clinical trial sits in five European Union countries for its ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (PD). The company is...

February 8, 2023

Developments

FDA clears Annovis Bio for Phase 2/3 AD study

The FDA approved the development plan and study protocol for Annovis Bio (NYSE:ANVS) to proceed with a Phase 2/3 clinical study of buntanetap in moderate Alzheimer’s Disease (AD). In a statement, Maria...

October 6, 2022

Developments

Annovis Bio receives additional U.S. patents

Annovis Bio (NYSE:ANVS) announced the publication of three granted U.S. patents that cover methods of treating amyloid lateral sclerosis, Huntington’s disease, and prion diseases by administering buntanetap. The...

September 13, 2022

Developments

First patient dosed in Annovis Bio Phase 3 trial in early PD

The first patient has been dosed in Annovis Bio’s (NYSE:ANVS) Phase 3 clinical trial evaluating its buntanetap in early Parkinson’s disease (PD). The Phase 3 trial will enroll 450 early PD patients to be treated...

August 24, 2022

Developments

Annovis Bio gets FDA okay for Phase 3 Parkinson’s trial

Annovis Bio, Inc. (NYSE:ANVS) received notice from the FDA that a Phase 3 clinical study with buntanetap in early Parkinson’s patients may proceed. The FDA accepted the final protocol and the clinical development...

July 7, 2022

Developments

Annovis Bio in pact with the National Institute on Aging

Annovis Bio (NYSE:ANVS) entered a cooperative research and development agreement with the NIH’s National Institute on Aging to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived...

April 29, 2022

Feature

Annovis Bio improving information highway of nerve cells to treat AD, PD

Annovis Bio (NYSE:ANVS) is developing a lead drug candidate, ANVS401, to inhibit more than one neurotoxic protein, improving the information highway of nerve cells, known as axonal transport, for the treatment of...

December 14, 2021

Markets

Maxim ups Annovis Bio PT to $45 from $12

Maxim Group raised its price target for Annovis Bio (NYSE American: ANVS) to $45 from $12, citing upcoming Phase 2a data evaluating ANVS401 in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients. The stock...

May 13, 2021

Markets

Maxim starts Annovis Bio at buy; PT $12

Maxim Group launched coverage of Annovis Bio (NYSE American:ANVS) with a “buy” rating and $12 price target. The stock closed at $5 on June 17. Annovis’ ANVS401 is a disease-modifying agent for chronic neurodegenerative...

June 18, 2020

Tag - ANVS

Annovis Bio to expand Phase 3 PD study of buntanetap to EU

FDA clears Annovis Bio for Phase 2/3 AD study

Annovis Bio receives additional U.S. patents

First patient dosed in Annovis Bio Phase 3 trial in early PD

Annovis Bio gets FDA okay for Phase 3 Parkinson’s trial

Annovis Bio in pact with the National Institute on Aging

Annovis Bio improving information highway of nerve cells to treat AD, PD

Maxim ups Annovis Bio PT to $45 from $12

Maxim starts Annovis Bio at buy; PT $12

General

More